BioSpace News Archive

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced new data from a preclinical study of its drug candidate CF602 in the treatment of erectile dysfunction in diabetes experimental model.

100% kidney substrate reduction at 12 months post-gene therapy in the first patient dosed with the plato ® gene therapy platform in FAB-GT 1 trial for Fabry disease One new patient dosed and three new patients enrolled in Fabry disease clinical trial since January 2021 Orphan drug designation received from European Commission for AVR-RD-04 for cystinosis and AVR-RD-01 for Fabry disease

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) will announce its financial results for 2020 on Thursday, 25 March 2021. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will present at the following upcoming virtual conferences.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from a secondary analysis of GALACTIC-HF ( G lobal Approach to Lowering A diverse Cardiac Outcomes Through Improving Contractility in Heart Failure) assessing the effect of omecamtiv mecarbil on clinical outcomes in relationship to patient baseline ejection fraction will be presented in a Late Breaking Clinical Trial session

Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced the publication of a peer-reviewed case report analyzing the clinical outcomes of Zofin treatment in three critically ill patients suffering from severe, multi-organ complications induced by COVID-19 infection.

Ms. Haukioja will leverage more than 25 years of progressive pharmaceutical experience to provide strategic guidance to ZYUS’ clinical trial programs

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ( “BioVaxys”), the world leader in haptenized protein vaccines for antiviral and cancer applications, announced today that it has entered into an agreement with Bioanalytical Systems, Inc. d/b/a Inotiv (“Inotiv”), a global Contract Research Organization (“CRO”)

Initiative aims to generate awareness about idiopathic hypersomnia and encourage those who may be struggling with the sleep disorder to have effective discussions with their healthcare providers and supporters about their condition

BIO-Europe Spring 2021 Kempen Life Sciences Conference 4 th SACHS Annual Neuroscience Innovation Forum 2021